Tomohide Tamura

Tomohide Tamura

UNVERIFIED PROFILE

Are you Tomohide Tamura?   Register this Author

Register author
Tomohide Tamura

Tomohide Tamura

Publications by authors named "Tomohide Tamura"

Are you Tomohide Tamura?   Register this Author

100Publications

2926Reads

36Profile Views

Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study.

Intern Med 2020 Feb 7;59(4):563-567. Epub 2019 Oct 7.

Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2779-19DOI Listing
February 2020

Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012-2014.

Jpn J Clin Oncol 2019 Dec 12. Epub 2019 Dec 12.

Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz167DOI Listing
December 2019

Congenital pulmonary veno-portal shunt.

Eur Heart J Cardiovasc Imaging 2019 Sep;20(9):1069

Department of Cardiology, St. Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ehjci/jez055DOI Listing
September 2019

Primary Synovial Sarcoma of the Mediastinum with Long-term Follow-up.

Intern Med 2019 May 10;58(10):1463-1465. Epub 2019 Jan 10.

Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2199-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548923PMC
May 2019

Septic pulmonary embolism caused by after a CO laser surgery for rhinitis.

BMJ Case Rep 2019 Mar 31;12(3). Epub 2019 Mar 31.

Division of Pulmonary Medicine, Thoracic Center, St Luke's International University, Chuo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-228420DOI Listing
March 2019

Yellow Nail Syndrome Patients with Diffuse Panbronchiolitis-like Pulmonary Manifestation.

Intern Med 2019 Feb 12;58(4):553-556. Epub 2018 Sep 12.

Division of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.1466-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421143PMC
February 2019

Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.

J Thorac Oncol 2019 02 1;14(2):e36-e38. Epub 2018 Nov 1.

Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.156DOI Listing
February 2019

Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Lung Cancer 2018 07 17;121:37-40. Epub 2018 Apr 17.

Thoracic Center, St. Luke's International Hospital, Chuo-ku, Tokyo 104-8560 Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.04.015DOI Listing
July 2018

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Oct 30;35(30):3449-3457. Epub 2017 Aug 30.

Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University, Seoul; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju-si, Republic of Korea; Claus-Peter Schneider, Zentralklinik Bad Berka, Bad Berka; Joachim Von Pawel, Asklepius Fachkliniken, Gauting; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pablo Fernando Gonzalez Mella, Centro de Investigaciones Clinicas, Universidad de Valparaíso and Fundación Arturo López Pérez, Santiago, Chile; Fabrice Barlesi, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Baohui Han, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai; Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China; Doina Elena Ganea, Spitalul Judetean De Urgenta Suceava, Sfântul loan cel Nou, Suceava, Romania; Vladimir Vladimirov, State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk; Natalia Fadeeva, Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Tomohide Tamura, St Luke's International Hospital, Tokyo, Japan; Pieter E. Postmus, University of Liverpool, Liverpool, United Kingdom; Kenneth O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia; and Justin Kopit, Mingshun Li, and Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.7629
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.7629DOI Listing
October 2017

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

J Clin Oncol 2017 May 15;35(14):1515-1521. Epub 2017 Mar 15.

Tomohide Tamura, St Luke's International Hospital; Yuichiro Ohe, National Cancer Center Hospital; Hiroshi Kuriki, Tadashi Shimada, and Tomohiro Tanaka, Chugai Pharmaceutical; Kengo Takeuchi, Japanese Foundation for Cancer Research; Makoto Nishio, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo; Katsuyuki Kiura, Okayama University Hospital, Okayama; Takashi Seto, National Kyusyu Cancer Center, Fukuoka; Kazuhiko Nakagawa, Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; Toyoaki Hida, Aichi Cancer Center, Nagoya; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Masao Harada, Hokkaido Cancer Center, Sapporo; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; and Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.5749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704PMC
May 2017

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.

Invest New Drugs 2017 04 8;35(2):207-216. Epub 2016 Dec 8.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0411-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352798PMC
April 2017

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2016 Nov 15;78(5):995-1002. Epub 2016 Sep 15.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3154-zDOI Listing
November 2016

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Invest New Drugs 2016 Feb 2;34(1):66-74. Epub 2015 Dec 2.

Department of Thoracic Oncology, National Cancer Centre Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0300-0DOI Listing
February 2016

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Int J Radiat Oncol Biol Phys 2016 Jan 26;94(1):155-162. Epub 2015 Sep 26.

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.09.026DOI Listing
January 2016

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Dec 3;76(6):1143-52. Epub 2015 Nov 3.

Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-015-2895-4
Publisher Site
http://dx.doi.org/10.1007/s00280-015-2895-4DOI Listing
December 2015

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Invest New Drugs 2015 Jun 18;33(3):632-40. Epub 2015 Mar 18.

Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo, 135-8550, Japan,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0227-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0227-5DOI Listing
June 2015

Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.

Mol Cancer Ther 2015 Jun 1;14(6):1414-23. Epub 2015 Apr 1.

Shien-Lab, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan. Department of Laboratory Medicine and Division of Clinical Research Support, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0625DOI Listing
June 2015

A phase I study of resminostat in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2015 Jun 7;75(6):1155-61. Epub 2015 Apr 7.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2741-8DOI Listing
June 2015

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.

Lung Cancer 2015 Jun 19;88(3):275-81. Epub 2015 Mar 19.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.03.010DOI Listing
June 2015

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

J Clin Oncol 2015 Jun 27;33(18):2051-61. Epub 2015 Apr 27.

All authors: National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.4953DOI Listing
June 2015

Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.

J Clin Oncol 2015 Feb 12;33(6):575-81. Epub 2015 Jan 12.

Tetsuya Abe and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata; Koji Takeda, Osaka City General Hospital; Shinzoh Kudoh, Osaka City University; Shinichiro Nakamura, West Japan Oncology Group Data Center; Kazuhiko Nakagawa, Kinki University, Osaka; Yuichiro Ohe, National Cancer Center Hospital East, Chiba; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroaki Okamoto, Yokohama Municipal Citizens Hospital, Kanagawa; Nobuyuki Yamamoto, Wakayama Medical University School of Medicine, Wakayama; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Koichi Minato, Gunma Cancer Center, Gunma; Toshiyuki Sawa, Gifu Municipal Hospital, Gifu; Yasuo Iwamoto, Hiroshima City Hospital, Hiroshima; Hideo Saka, Nagoya Medical Center; Masahiko Ando, Nagoya University Hospital, Aichi; Junki Mizusawa and Taro Shibata, Japan Clincal Oncology Group Data Center, National Cancer Center; Nagahiro Saijo, Japanese Society of Medical Oncology; and Tomohide Tamura, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.8627DOI Listing
February 2015

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Jul 22;74(1):15-23. Epub 2014 Apr 22.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-014-2467-z
Publisher Site
http://dx.doi.org/10.1007/s00280-014-2467-zDOI Listing
July 2014

Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.

Cancer Lett 2014 Jun 7;347(2):196-203. Epub 2014 Mar 7.

Shien-lab, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Genomic Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.02.025DOI Listing
June 2014

A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).

Jpn J Clin Oncol 2014 Apr 27;44(4):379-82. Epub 2014 Jan 27.

*Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyt233DOI Listing
April 2014

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

J Clin Oncol 2014 Apr 17;32(12):1262-8. Epub 2014 Mar 17.

Miyako Satouchi, Hyogo Cancer Center, Akashi; Yoshikazu Kotani, Kobe University Graduate School of Medicine, Kobe; Taro Shibata and Haruhiko Fukuda, Japan Clinical Oncology Group Data Center, Multi-Institutional Clinical Trial Support Center, National Cancer Center; Yuichiro Ohe, National Cancer Center Hospital East; Makoto Nishio, Cancer Institute Hospital, Japanese Foundation For Cancer Research; Tomohide Tamura, National Cancer Center Hospital; Nagahiro Saijo, Japanese Society of Medical Oncology, Tokyo; Masahiko Ando, Kyoto University School of Public Health, Kyoto; Kazuhiko Nakagawa, Kinki University School of Medicine; Koji Takeda, Osaka City General Hospital; Tatsuo Kimura, Graduate School of Medicine, Osaka City University; Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Yukito Ichinose, National Hospital Organization Kyushu Cancer Center, Fukuoka; Toyoaki Hida, Aichi Cancer Center, Nagoya; Koichi Minato, Gunma Cancer Center, Gunma; and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata, Japan.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.53.5153
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.53.5153DOI Listing
April 2014

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Mar 18;73(3):511-6. Epub 2014 Jan 18.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2375-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931937PMC
March 2014

Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer.

Jpn J Clin Oncol 2014 Feb 13;44(2):191-4. Epub 2013 Dec 13.

*Division of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 1040045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyt192DOI Listing
February 2014

Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study.

Jpn J Clin Oncol 2013 Nov 4;43(11):1105-9. Epub 2013 Sep 4.

*Division of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyt122DOI Listing
November 2013

Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint.

Biochem Biophys Res Commun 2013 Nov 6;441(4):793-8. Epub 2013 Nov 6.

Shien-Lab, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; Department of Bioengineering, Graduate School of Engineering, Osaka City University, 3-3-138 Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2013.10.134DOI Listing
November 2013

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Sep 17;72(3):577-84. Epub 2013 Jul 17.

Division of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2228-4DOI Listing
September 2013

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.

Invest New Drugs 2013 Jun 28;31(3):677-84. Epub 2012 Jul 28.

Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9860-4DOI Listing
June 2013

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Jun 25;71(6):1645-55. Epub 2013 Apr 25.

Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2165-2DOI Listing
June 2013

Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.

Jpn J Clin Oncol 2013 Apr 13;43(4):422-5. Epub 2013 Feb 13.

Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjc
Publisher Site
http://dx.doi.org/10.1093/jjco/hyt012DOI Listing
April 2013

Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.

Cancer Sci 2013 Jan 8;104(1):93-7. Epub 2012 Nov 8.

Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12028DOI Listing
January 2013

Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.

Jpn J Clin Oncol 2012 Dec 17;42(12):1187-91. Epub 2012 Oct 17.

Division of Pharmacy, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hys170DOI Listing
December 2012

A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.

Cancer Chemother Pharmacol 2012 Oct 10;70(4):559-65. Epub 2012 Aug 10.

Internal Medicine and Thoracic Oncology, Division of Internal Medicine, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-1932-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456941PMC
October 2012